49 results
DRS/A
EX-10.5
CNTB
Connect Biopharma Holdings Ltd
26 Jan 21
Draft registration statement (amended)
12:00am
to bring such action, the
furnishing of a power of attorney. Neither party shall have the right to settle any patent infringement litigation under … of such litigation, after reimbursement of any litigation expenses of Company and Licensor, shall be retained by the party that brought and controlled such litigation
F-1
EX-10.5
CNTB
Connect Biopharma Holdings Ltd
26 Feb 21
Registration statement (foreign)
4:56pm
to bring such action, the
furnishing of a power of attorney. Neither party shall have the right to settle any patent infringement litigation under … of such litigation, after reimbursement of any litigation expenses of Company and Licensor, shall be retained by the party that brought and controlled such litigation
F-1/A
CNTB
Connect Biopharma Holdings Ltd
18 Mar 21
Registration statement (foreign) (amended)
6:15am
. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover … media attention;
difficulty attracting or withdrawal of clinical trial participants;
costs to defend the related litigation;
a diversion
6-K
CNTB
Connect Biopharma Holdings Ltd
10 Jun 22
Current report (foreign)
6:05am
harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Exhibit Index
Exhibit
No.
Description
Exhibit 99.1
2022
20-F
wnq7c2 g5ue
31 Mar 22
Annual report (foreign)
4:33pm
DRS
jda2qe
17 Dec 20
Draft registration statement
12:00am
6-K
r8894
1 Jun 23
Current report (foreign)
4:24pm
DRS/A
43p9gwi0lnjlx
26 Jan 21
Draft registration statement (amended)
12:00am
F-1/A
kv04os fspfei
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
rq9n2z5r4c
30 Dec 22
Connect Biopharma Provides Business and Clinical Development Program Update
8:00am
424B4
z8ejby
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1
dgxik2r3hwpkalylajsn
26 Feb 21
Registration statement (foreign)
4:56pm
6-K
gtrlzpgi2053fnd
27 Aug 21
Current report (foreign)
4:10pm
F-1/A
EX-10.2
m1h2s3f
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
EX-99.1
3vepst1l126kbm1s5 s8
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
0g3tyg8azipd5bm
5 May 22
Current report (foreign)
6:04am
6-K
41wwdr0
11 Jul 22
Current report (foreign)
4:30pm
6-K
g6ktndzyw32kbi8be8wt
4 Oct 22
Current report (foreign)
7:16am